# Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction

> **NCT03843515** · PHASE1 · UNKNOWN · sponsor: **Amsterdam UMC, location VUmc** · enrollment: 17 (actual)

## Conditions studied

- Oral Cavity Squamous Cell Carcinoma

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03843515
- **Lead sponsor:** Amsterdam UMC, location VUmc
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-11
- **Primary completion:** 2021-11-30
- **Final completion:** 2022-08-31
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2021-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03843515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03843515, "Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03843515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*